Identification

Name
Desmopressin
Accession Number
DB00035
Description

Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney 6. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems.

Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH 2. It has been employed clinically since 1972 and is available in various formulations including intranasal solution, intravenous solution, oral tablet and oral lyophilisate 3. Desmopressin is indicated for the treatment of polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. It was also newly approved for the treatment of mild classical hemophilia and von Willebrand's disease for minor surgeries. The active ingredient in most formulations is desmopressin acetate. Nocdurna, or desmopressin acetate, was approved by the FDA on June 21st, 2018 for the treatment of nocturia due to nocturnal polyuria in adults. It is available as a sublingual tablet.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 1069.22
Monoisotopic: 1068.426955905
Chemical Formula
C46H64N14O12S2
Synonyms
  • 1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin
  • 1-deamino-8-D-arginine vasopressin
  • 1-desamino-8-D-arginine vasopressin
  • dDAVP
  • Desmopresina
  • Desmopressin
  • Desmopressine
  • Desmopressinum

Pharmacology

Indication
  • Indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void (intranasal).

  • Indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral).

  • Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% or mild to moderate classic von Willebrand's Disease (Type I) with factor VIII levels greater than 5% during surgical procedures and postoperatively to maintain hemostasis (parenteral).

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

By mimicking the actions of endogenous ADH, desmopressin acts as a selective agonist of V2 receptors expressed in the renal collecting duct (CD) to increase water re-absorption and reduce urine production. Desmopressin has been shown to be more potent than ADH in increasing plasma levels of factor VIII activity in patients with hemophilia and von Willebrand's disease Type I 8. Desmopressin demonstrates markedly diminished pressor activity. Desmopressin administered intranasally has an antidiuretic effect about one-tenth that of an equivalent dose administered by injection 7.

Mechanism of action

Upon binding of desmopressin to V2 receptors in the basolateral membrane of the cells of the distal tubule and collecting ducts of the nephron, adenylyl cyclase is stimulated. The resulting intracellular cascades in the collecting duct lead to increased rate of insertion of water channels, called aquaporins, into the lumenal membrane and enhanced the permeability of the membrane to water 6.

TargetActionsOrganism
AVasopressin V2 receptor
agonist
Humans
AVasopressin V1a receptorNot AvailableHumans
AVasopressin V1b receptorNot AvailableHumans
Absorption

Following nasal spray administration of 0.83 mcg and 1.66 mcg, median time to peak plasma concentrations (Tmax) was 0.25 and 0.75 hour, respectively Label. The peak plasma concentration was approximately 4.00 (± 3.85) pg/mL and 9.11 (± 6.90) pg/mL, respectively Label. The bioavailability of 1.5 mg/mL desmopressin administered by the intranasal route was between 3.3 and 4.1% 8.

The absolute bioavailability of orally administered desmopressin varies between 0.08% and 0.16% where the mean maximum plasma concentration is reached within 2 hours 9.

Volume of distribution

The distribution volume of orally administered desmopressin is 0.2 – 0.32 l/kg 9. It is not reported to cross the blood-brain barrier.

Protein binding

Following radioiodination (125I) in the N-terminal, the fraction of plasma protein binding of desmopressin was reported to be 17.3 ± 1.5% in a pharmacokinetic study involving healthy subjects 5.

Metabolism

In vitro, in human liver microsome preparations, it has been shown that no significant amount of desmopressin is metabolised in the liver and thus human liver metabolism in vivo is not likely to occur 9.

Route of elimination

Desmopressin is mainly excreted in the urine. About 65% of the amount of desmopressin absorbed after oral administration could be recovered in the urine within 24 hours 9.

Half-life

Following an intranasal dose of 1.66 mcg of desmopressin, the median apparent terminal half-life was 2.8 hours Label. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment Label. The oral terminal half life of desmopressin ranges from 2 to 3.11 hours 9.

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Intravenous TDLo in humans is reported to be 0.3 µg/kg/10M MSDS. Desmopressin is associated with hyponatremia in case of overdose, which may require temporary or permanent discontinuation of the therapy depending on severity. The effects of hyponatremia include seizure, altered mental status (confusion, drowsiness or continuing headache), cardiac arrhythmias and worsening edema. Other signs of overdose may include oliguria and rapid weight gain due to fluid retention Label. In case of overdose, reduce the dose or frequency of drug administration, or discontinue use if appropriate. Assessment of serum sodium and initiation of appropriate medical treatment is recommended.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirDesmopressin may decrease the excretion rate of Abacavir which could result in a higher serum level.
AcarboseDesmopressin may decrease the excretion rate of Acarbose which could result in a higher serum level.
AcebutololDesmopressin may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Aceclofenac is combined with Desmopressin.
AcemetacinThe risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Acemetacin is combined with Desmopressin.
AcetaminophenDesmopressin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidThe risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Acetylsalicylic acid is combined with Desmopressin.
AclidiniumDesmopressin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
AcrivastineDesmopressin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Product Ingredients
IngredientUNIICASInChI Key
Desmopressin acetateXB13HYU18U62357-86-2YNKFCNRZZPFMEX-XHPDKPNGSA-N
Desmopressin acetate anhydrous1K12647SFC62288-83-9MLSVJHOYXJGGTR-IFHOVBQLSA-N
Product Images
International/Other Brands
Adiuretin (Ferring) / DesmoMelt (Ferring)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
DdavpInjection4 ug/1mLIntravenousFerring Pharmaceuticals Inc.1984-03-30Not applicableUS flag
DdavpTablet0.1 mg/1OralFerring Pharmaceuticals Inc.1995-09-06Not applicableUS flag
DdavpSpray0.1 ug/1mLNasalFerring Pharmaceuticals Inc.1978-02-212022-06-30US flag
DdavpTablet0.1 mg/1Oralsanofi-aventis U.S. LLC1995-09-062016-09-30US flag
DdavpInjection4 ug/1mLIntravenousFerring Pharmaceuticals Inc.1984-03-30Not applicableUS flag
DdavpSolution4 ug/1mLIntravenoussanofi-aventis U.S. LLC1984-03-302017-10-31US flag
DdavpTablet0.2 mg/1OralFerring Pharmaceuticals Inc.1995-09-06Not applicableUS flag
DdavpSolution0.1 mg/1mLNasalsanofi-aventis U.S. LLC1978-02-212015-11-30US flag
DdavpSpray0.1 mg/1mLNasalFerring Pharmaceuticals Inc.1978-02-212021-07-31US flag
DdavpTablet0.2 mg/1Oralsanofi-aventis U.S. LLC1995-09-062016-01-31US flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Desmopressin AcetateTablet0.2 mg/1OralNorthStar Rx LLC2015-05-28Not applicableUS flag
Desmopressin AcetateTablet0.2 mg/1OralTeva2006-01-272017-12-31US flag00093 7317 01 nlmimage10 02360120
Desmopressin AcetateTablet0.1 mg/1OralBluePoint Laboratories2014-02-27Not applicableUS flag
Desmopressin AcetateTablet0.2 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2015-05-28Not applicableUS flag
Desmopressin AcetateTablet0.1 mg/1OralAmerincan Health Packaging2010-01-122012-11-30US flag
Desmopressin AcetateTablet0.2 mg/1OralApotex Corp.2006-03-07Not applicableUS flag
Desmopressin AcetateTablet0.1 mg/1OralAmerican Health Packaging2012-11-06Not applicableUS flag00591 2464 01 nlmimage10 fc397e2b
Desmopressin AcetateTablet0.1 mg/1OralActavis Pharma, Inc.2011-08-15Not applicableUS flag0591 246420180907 15195 1e84r8f
Desmopressin AcetateTablet0.2 mg/1OralBarr Laboratories2005-07-012010-08-31US flag
Desmopressin AcetateInjection, solution4 ug/1mLIntravenous; SubcutaneousSun Pharmaceutical Industries, Inc.2014-02-20Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
H01BA02 — Desmopressin
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
ENR1LLB0FP
CAS number
16679-58-6
InChI Key
NFLWUMRGJYTJIN-PNIOQBSNSA-N
InChI
InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1
IUPAC Name
(2R)-2-{[(2S)-1-[(4R,7S,10S,13S,16S)-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-5-carbamimidamido-N-(carbamoylmethyl)pentanamide
SMILES
NC(=O)CC[[email protected]@H]1NC(=O)[[email protected]](CC2=CC=CC=C2)NC(=O)[[email protected]](CC2=CC=C(O)C=C2)NC(=O)CCSSC[[email protected]](NC(=O)[[email protected]](CC(N)=O)NC1=O)C(=O)N1CCC[[email protected]]1C(=O)N[[email protected]](CCCNC(N)=N)C(=O)NCC(N)=O

References

Synthesis Reference

Krister Larsson, Thomas Mellbrand, Birgitta Mornstam, Jan Roschester, Jan-Ake Skoldback, "High purity desmopressin produced in large single batches." U.S. Patent US5674850, issued November, 1991.

US5674850
General References
  1. Leissinger C, Becton D, Cornell C Jr, Cox Gill J: High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258-66. [PubMed:11380629]
  2. Richardson DW, Robinson AG: Desmopressin. Ann Intern Med. 1985 Aug;103(2):228-39. [PubMed:3893256]
  3. Vande Walle J, Stockner M, Raes A, Norgaard JP: Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf. 2007 Sep;2(3):232-8. [PubMed:18690973]
  4. Agerso H, Seiding Larsen L, Riis A, Lovgren U, Karlsson MO, Senderovitz T: Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol. 2004 Oct;58(4):352-8. doi: 10.1111/j.1365-2125.2004.02175.x. [PubMed:15373927]
  5. Lundin S, Broeders A, Melin P: Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers. Clin Endocrinol (Oxf). 1993 Sep;39(3):369-74. [PubMed:8222299]
  6. 32. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 399-400). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
  7. DDVAP Nasal Spray FDA Label [Link]
  8. Stimate (desmopressin acetate) nasal spray FDA Label [Link]
  9. UKPAR for Desmopressin acetate 100mcg and 200mcg Tablets [Link]
Human Metabolome Database
HMDB0014260
KEGG Drug
D00291
KEGG Compound
C06944
ChemSpider
4470602
BindingDB
50205308
RxNav
3251
ChEBI
4450
ChEMBL
CHEMBL1429
Therapeutic Targets Database
DNC000526
PharmGKB
PA449237
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Desmopressin
AHFS Codes
  • 68:28.00 — Pituitary
FDA label
Download (1.22 MB)
MSDS
Download (26.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticMonosymptomatic Nocturnal Enuresis1
4CompletedPreventionBlood Loss,Surgical / Hemorrhage / Postoperative Hemorrhages1
4CompletedPreventionPatients Undergoing Endoscopic Sinus Surgery1
4CompletedPreventionRenal Failure1
4CompletedTreatmentAcquired Von Willebrand Disease Secondary to Severe Aortic Stenosis / Heye´s Syndrome / Severe Aortic Stenosis1
4CompletedTreatmentEnuresis / Polyuria1
4CompletedTreatmentHemophilia A1
4CompletedTreatmentMonosymptomatic Nocturnal Enuresis1
4CompletedTreatmentNocturia1
4CompletedTreatmentNocturnal Enuresis1

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
  • Ferring pharmaceuticals inc
  • Bausch and lomb pharmaceuticals inc
  • Apotex inc richmond hill
  • Csl behring llc
  • Apotex inc etobicoke site
  • Teva pharmaceuticals usa
  • Watson laboratories inc
Packagers
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Arcola Laboratories
  • Bachem Inc.
  • Barr Pharmaceuticals
  • Bausch & Lomb Inc.
  • CSL Behring LLC
  • Ferring Pharmaceuticals Inc.
  • Hospira Inc.
  • Kaiser Foundation Hospital
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Promex Medical Inc.
  • Rechon Life Science AB
  • Sanofi-Aventis Inc.
  • Sicor Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Watson Pharmaceuticals
Dosage Forms
FormRouteStrength
SolutionIntravenous4 ug/1mL
SprayNasal0.1 ug/1mL
LiquidIntramuscular; Intravenous; Subcutaneous
Tablet, orally disintegratingSublingual
SolutionNasal
Aerosol, meteredNasal
TabletOral
SolutionIntrasinal; Nasal0.1 mg
SolutionIntravenous4 mcg
SolutionNasal; Respiratory (inhalation)89 mcg
InjectionIntravenous4 ug/1mL
InjectionIntravenous; Subcutaneous4 ug/1mL
InjectionIntravenous; Subcutaneous40 ug/10mL
Injection, solutionIntravenous; Subcutaneous4 ug/1mL
Injection, solutionIntravenous; Subcutaneous40 ug/10mL
PowderNot applicable1 g/1g
SolutionNasal0.1 mg/1mL
SprayNasal0.1 mg/1mL
SprayNasal10 ug/1
SprayNasal10 ug/0.1mL
TabletOral0.1 mg/1
TabletOral0.2 mg/1
Spray, meteredNasal
SprayNasal0.1 %
SolutionSublingual0.4 mg
Injection, solutionIntravenous; Subcutaneous40 mcg
Injection, solutionParenteral20 MCG/1ML
Injection, solutionParenteral4 MCG/0.5ML
SolutionIntramuscular; Intravenous; Subcutaneous20 cg
Tablet, solubleOral120 cg
SolutionIntrasinal; Nasal10 mg
SolutionIntramuscular; Intravenous; Subcutaneous4 cg
SolutionIntravenous; Subcutaneous0.025 mg
Injection, solution100 mcg/1mL
Injection, solution4 mcg/1mL
Solution; sprayNasal10 mg/100mL
Tablet200 mcg
TabletOral100 mcg
SolutionNasal; Respiratory (inhalation)0.089 mg
SprayNasal0.1 mg/ml
Injection, solutionIntramuscular; Intravenous4 mcg/ml
TabletOral120 mcg
PowderOral120 cg
PowderOral120 µg
PowderOral240 µg
TabletOral60 mcg
PowderOral60 µg
SprayNasal
Tablet
Injection, solution4 MCG/ML
Solution / dropsNasal0.1 MG/ML
SprayNasal50 MCG/ML
Tablet0.1 MG
Tablet0.2 MG
Tablet120 MCG
Tablet240 MCG
Tablet60 MCG
TabletSublingual27.7 ug/1
TabletSublingual55.3 ug/1
Tablet, orally disintegratingSublingual25 mcg
Tablet, orally disintegratingSublingual50 mcg
PowderOral25 Mikrogramm
PowderOral50 Mikrogramm
Spray, meteredNasal0.83 ug/1
Spray, meteredNasal1.66 ug/1
SolutionIntravenous; Subcutaneous15 mcg
Injection, solutionIntravenous; Subcutaneous15 mcg/ml
Injection, solutionIntravenous; Subcutaneous30 mcg/2ml
LiquidIntravenous; Subcutaneous
TabletOral0.1 MG
TabletOral0.2 MG
Spray, meteredNasal1.5 mg/1mL
Prices
Unit descriptionCostUnit
Stimate 1.5 mg/ml nasal spray334.2USD ml
Ddavp 0.01% nasal spray50.76USD ml
Ddavp 4 mcg/ml ampul43.27USD ml
Desmopressin 0.1 mg/ml spray39.6USD ml
Ddavp 0.1 mg/ml Solution21.26USD ml
Octostim 150 mcg/dose Metered Dose Spray17.39USD dose
Ddavp 4 mcg/ml11.33USD ml
Desmopressin ac 4 mcg/ml amp7.28USD ml
Desmopressin ac 4 mcg/ml vial7.08USD ml
Ddavp 0.2 mg tablet6.43USD tablet
Ddavp 0.1 mg tablet4.47USD tablet
Desmopressin acetate 0.2 mg tablet4.44USD tablet
Desmopressin acetate 0.1 mg tablet3.08USD tablet
Ddavp 0.2 mg Tablet2.98USD tablet
Ddavp 10 mcg/dose Metered Dose Spray2.13USD dose
Apo-Desmopressin 0.2 mg Tablet1.67USD tablet
Novo-Desmopressin 0.2 mg Tablet1.67USD tablet
Pms-Desmopressin 0.2 mg Tablet1.67USD tablet
Ddavp 0.1 mg Tablet1.49USD tablet
Apo-Desmopressin 10 mcg/dose Metered Dose Spray1.48USD dose
Apo-Desmopressin 0.1 mg Tablet0.83USD tablet
Novo-Desmopressin 0.1 mg Tablet0.83USD tablet
Pms-Desmopressin 0.1 mg Tablet0.83USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US7022340No2006-04-042023-04-30US flag
US5500413No1996-03-192013-06-29US flag
CA2484724No2007-01-162023-05-07Canada flag
CA2486833No2005-08-022024-04-30Canada flag
US9539302No2017-01-102030-06-15US flag
US7799761No2010-09-212024-09-26US flag
US7405203No2008-07-292023-05-06US flag
US7579321No2009-08-252023-05-06US flag
US9919025No2018-03-202023-05-07US flag
US9220747No2015-12-292023-05-07US flag
US9504647No2016-11-292023-05-07US flag
US9974826No2018-05-222030-04-13US flag
US8802624No2014-08-122023-12-29US flag
US7560429No2009-07-142024-02-02US flag
US7947654No2011-05-242023-12-29US flag
US10137167No2018-11-272029-05-21US flag
US10307459No2019-06-042023-05-07US flag
Additional Data Available
  • Filed On
    Filed On
    Available for Purchase

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.11 mg/mLALOGPS
logP-1ALOGPS
logP-6.1ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)9.5ChemAxon
pKa (Strongest Basic)11.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count15ChemAxon
Hydrogen Donor Count14ChemAxon
Polar Surface Area435.41 Å2ChemAxon
Rotatable Bond Count19ChemAxon
Refractivity279.78 m3·mol-1ChemAxon
Polarizability104.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.7979
Blood Brain Barrier-0.8866
Caco-2 permeable-0.7612
P-glycoprotein substrateSubstrate0.8242
P-glycoprotein inhibitor INon-inhibitor0.7864
P-glycoprotein inhibitor IINon-inhibitor0.9237
Renal organic cation transporterNon-inhibitor0.5915
CYP450 2C9 substrateNon-substrate0.7833
CYP450 2D6 substrateNon-substrate0.7901
CYP450 3A4 substrateNon-substrate0.5497
CYP450 1A2 substrateNon-inhibitor0.8383
CYP450 2C9 inhibitorNon-inhibitor0.7906
CYP450 2D6 inhibitorNon-inhibitor0.8735
CYP450 2C19 inhibitorNon-inhibitor0.765
CYP450 3A4 inhibitorNon-inhibitor0.7663
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9331
Ames testNon AMES toxic0.6679
CarcinogenicityNon-carcinogens0.8428
BiodegradationNot ready biodegradable0.9445
Rat acute toxicity2.7183 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.83
hERG inhibition (predictor II)Inhibitor0.6036
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Vasopressin receptor activity
Specific Function
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.
Gene Name
AVPR2
Uniprot ID
P30518
Uniprot Name
Vasopressin V2 receptor
Molecular Weight
40278.57 Da
References
  1. Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F: Identification of novel selective V2 receptor non-peptide agonists. Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12. [PubMed:18761325]
  2. Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38. [PubMed:16333859]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
General Function
Vasopressin receptor activity
Specific Function
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behavi...
Gene Name
AVPR1A
Uniprot ID
P37288
Uniprot Name
Vasopressin V1a receptor
Molecular Weight
46799.105 Da
References
  1. Loichot C, Cazaubon C, De Jong W, Helwig JJ, Nisato D, Imbs JL, Barthelmebs M: Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):319-26. [PubMed:10731046]
  2. Mechaly I, Laurent F, Portet K, Serrano J, Cros G: Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. [PubMed:10594321]
  3. Barthelmebs M, Krieger JP, Grima M, Nisato D, Imbs JL: Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney. Eur J Pharmacol. 1996 Oct 31;314(3):325-32. [PubMed:8957254]
  4. Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
General Function
Vasopressin receptor activity
Specific Function
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.
Gene Name
AVPR1B
Uniprot ID
P47901
Uniprot Name
Vasopressin V1b receptor
Molecular Weight
46970.345 Da
References
  1. Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. [PubMed:15613460]
  2. Dinan TG, O'Brien S, Lavelle E, Scott LV: Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med. 2004 Jan;34(1):169-72. [PubMed:14971638]
  3. Craighead M, Milne R, Campbell-Wan L, Watson L, Presland J, Thomson FJ, Marston HM, Macsweeney CP: Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res. 2008;170:527-35. doi: 10.1016/S0079-6123(08)00440-8. [PubMed:18655906]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. [PubMed:15644490]

Drug created on June 13, 2005 07:24 / Updated on November 23, 2020 09:08

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates